AlloVir, Inc. (NASDAQ:ALVR - Get Free Report)'s stock price fell 1.2% on Wednesday . The stock traded as low as $0.49 and last traded at $0.51. 460,323 shares changed hands during trading, a decline of 23% from the average session volume of 600,335 shares. The stock had previously closed at $0.51.
AlloVir Price Performance
The company has a market cap of $53.16 million, a price-to-earnings ratio of -0.52 and a beta of 0.59. The business's 50-day simple moving average is $0.70 and its 200-day simple moving average is $0.74.
AlloVir (NASDAQ:ALVR - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10.
Institutional Investors Weigh In On AlloVir
Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in shares of AlloVir by 127.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company's stock worth $74,000 after buying an additional 54,900 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in AlloVir during the second quarter worth about $55,000. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of AlloVir by 152.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company's stock worth $36,000 after purchasing an additional 30,072 shares during the period. 66.05% of the stock is currently owned by hedge funds and other institutional investors.
About AlloVir
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Further Reading
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
